Peran Pemeriksaan Imunohistokimia dalam Diagnosis dan Prognosis Kanker Payudara

Authors

  • I Made Agus Setiawan Indonesian Medical Association

DOI:

https://doi.org/10.55175/cdk.v50i8.667

Keywords:

Diagnosis, imunohistokimia, kanker payudara, prognosis

Abstract

Kanker payudara adalah kanker dengan jumlah penderita terbanyak di Indonesia. Pemeriksaan imunohistokimia saat ini menjadi pemeriksaan penting karena dapat membantu diagnosis, menentukan terapi, dan prognosis kanker payudara.

 

Breast cancer is the most frequent cancer in Indonesia. Immunohistochemistry examination is currently become an important tool in diagnosis, therapy, and prognosis of breast cancer.

Downloads

Download data is not yet available.

References

Breast Cancer Facts and Figures 2017-2018. American Cancer Society [Internet]. 2017. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf

Kementerian Kesehatan Republik Indonesia. Kanker payudara paling banyak di Indonesia, Kemenkes targetkan pemerataan layanan kesehatan [Internet]. 2022. Available from: https://www.kemkes.go.id/article/view/22020400002/kanker-payudara-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan.html

Watkins EJ. Overview of breast cancer. J Am Acad Physician Assistant 2019;32(10):13-7.

Bonacho T, Rodrigues F. Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: A review. Biotechnic and Histochemistry 2019;95:71-91.

Chand P, Garg A, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. Nigerian J Surg. 2018;24:100-6.

Magaki S. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289-98.

Behairy M, Gabal SM, Negm MS. Breast cancer human epidermal growth factor receptor 2 mRNA molecular testing compared to immunohistochemistry with correlation to neoadjuvant therapy response. Macedonian J Med Sci. 2022;10(A):352-6.

Adanilfe A, Amegbor K, Doh K, Darre T. Breast cancer in Togolese women: Immunohistochemistry subtypes. BMC Women’s Health 2020;20:261.

Ariabod V, Sohooli M, Shekouhi R, Payan K. Assessment of breast cancer immunohistochemical properties with demographics and pathological features: A retrospective study. Int J Cancer Manag. 2021;14:1-7.

Sahay A, Patil A, Desai S.B. How we use immunohistochemistry to arrive at a diagnosis in breast lesions. Ind J Med Paediatric Oncol. 2022;43:114-9.

Hartati L, Lubis ND, Lukito JS. Akurasi P63 dalam membedakan lesi epitel jinak dan lesi epitel ganas payudara. Maj Patologi 2012;21(1):32-7.

Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol. 2014;5(3):382-92.

Louhichi T, Saad H, Dhiab MB, Ziadi S, Trimeche M. Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype. BMC Cancer 2018;18(49):1-9.

Omar E, Husain NE, Ismail A. The role of immunohistochemistry in the workup of malignant neoplasms of unknown primary origin at Khartoum Oncology Hospital. Asian Pac J Cancer Care 2021;6(4):441-7.

Li Z, Dabbs DJ. Avoiding “false positive” and “false negative” immunohistochemical results in breast pathology. Pathobiology 2022;89:309-23.

Zilenaite , Rasmusson A, Augulis R, Besusparis J, Laurinaviciene A, Plancoulaine B, et al. Independent prognostic value of intratumoral heterogeneity and immune response features by automated digital immunohistochemistry analysis in early hormone receptor-positive breast carcinoma. Frontiers in Oncology 2020;10:1-13.

Downloads

Published

02-08-2023

How to Cite

I Made Agus Setiawan. (2023). Peran Pemeriksaan Imunohistokimia dalam Diagnosis dan Prognosis Kanker Payudara. Cermin Dunia Kedokteran, 50(8), 443–446. https://doi.org/10.55175/cdk.v50i8.667